Exploring the conformational dynamics and thermodynamics of EGFR S768I and G719X+S768I mutations in non-small cell lung cancer: An in silico approaches

被引:1
|
作者
Wang, Jun-Ling [2 ]
Liu, Ming-Sheng [3 ]
Fu, Yu-Dong [4 ]
Kan, Qiang-Bo [4 ]
Li, Chun-Yan [5 ]
Ma, Rong [2 ]
Fang, Zhe-Wei [2 ]
Liu, Hong-Xia [2 ]
Li, Meng-Xian [2 ]
Lv, Jia-Ling [5 ]
Sang, Peng [6 ]
Zhang, Chao [1 ]
Li, Hong-Wei [1 ]
机构
[1] Kunming Med Univ, Affiliated Qujing Hosp, Dept Oncol, Yuanlin Rd 1, Qujing 655000, Peoples R China
[2] Kunming Med Univ, Affiliated Qujing Hosp, Clin Lab, Qujing 655000, Peoples R China
[3] Kunming Med Univ, Affiliated Qujing Hosp, Dept Urol Surg, Qujing 655000, Peoples R China
[4] Kunming Med Univ, Affiliated Qujing Hosp, Dept Thorac Surg, Qujing 655000, Peoples R China
[5] Kunming Med Univ, Affiliated Qujing Hosp, Dept Oncol, Qujing 655000, Peoples R China
[6] Dali Univ, Sch Life Sci, Dali 671003, Peoples R China
来源
OPEN LIFE SCIENCES | 2023年 / 18卷 / 01期
关键词
epidermal growth factor receptor G719X and S768I mutations; non-small cell lung cancer; molecular dynamics simulation; conformation; free energy landscape; MOLECULAR-DYNAMICS;
D O I
10.1515/biol-2022-0768
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Non-small cell lung cancer (NSCLC) is often driven by mutations in the epidermal growth factor receptor (EGFR) gene. However, rare mutations such as G719X and S768I lack standard anti-EGFR targeted therapies. Understanding the structural differences between wild-type EGFR and these rare mutants is crucial for developing EGFR-targeted drugs. We performed a systematic analysis using molecular dynamics simulations, essential dynamics (ED), molecular mechanics Poisson-Boltzmann surface area, and free energy calculation methods to compare the kinetic properties, molecular motion, and free energy distribution between wild-type EGFR and the rare mutants' structures G719X-EGFR, S768I-EGFR, and G719X + S768I-EGFR. Our results showed that S768I-EGFR and G719X + S768I-EGFR have higher global and local conformational flexibility and lower thermal and global structural stability than WT-EGFR. ED analysis revealed different molecular motion patterns between S768I-EGFR, G719X + S768I-EGFR, and WT-EGFR. The A-loop and alpha C-helix, crucial structural elements related to the active state, showed a tendency toward active state development, providing a molecular mechanism explanation for NSCLC caused by EGFR S768I and EGFR G719C + S768I mutations. The present study may be helpful in the development of new EGFR-targeted drugs based on the structure of rare mutations. Our findings may aid in developing new targeted treatments for patients with EGFR S768I and EGFR G719X + S768I mutations.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements
    Cooper, Wendy A.
    O'Toole, Sandra
    Boyer, Michael
    Horvath, Lisa
    Mahar, Annabelle
    PATHOLOGY, 2011, 43 (02) : 103 - 115
  • [22] The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non-small cell lung cancer with sensitive EGFR mutations
    Jiang, Yu
    Lin, Yuechun
    Fu, Wenhai
    He, Qihua
    Liang, Hengrui
    Zhong, Ran
    Cheng, Ran
    Li, Bingliang
    Wen, Yaokai
    Wang, Huiting
    Li, Jianfu
    Li, Caichen
    Xiong, Shan
    Chen, Songan
    Xiang, Jianxing
    Mann, Michael J.
    He, Jianxing
    Liang, Wenhua
    ECLINICALMEDICINE, 2023, 64
  • [23] Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial
    Riudavets, Mariona
    Naigeon, Marie
    Texier, Matthieu
    Dorta, Miriam
    Barlesi, Fabrice
    Mazieres, Julien
    Varga, Andrea
    Cassard, Lydie
    Boselli, Lisa
    Grivel, Jonathan
    NgoCamus, Maud
    Lacroix, Ludovic
    Mezquita, Laura
    Besse, Benjamin
    Chaput, Nathalie
    Planchard, David
    LUNG CANCER, 2022, 166 : 255 - 264
  • [24] Phase I/II study of docetaxel and S-1 in patients with previously treated non-small cell lung cancer
    Atagi, Shinji
    Kawahara, Masaaki
    Kusunoki, Yoko
    Takada, Minoru
    Kawaguchi, Tomoya
    Okishio, Kyoiti
    Kubo, Akihito
    Uehira, Kazutaka
    Yumine, Katsuyuki
    Tomizawa, Yoshio
    Saito, Ryusei
    Fukai, Shimao
    Komatsu, Hikotaro
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (09) : 1012 - 1017
  • [25] Three Novel EGFR Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report
    Li, Huiying
    Yu, Tingting
    Lin, Yongjuan
    Xie, Yu
    Feng, Jie
    Huang, Mingmin
    Guo, Aibin
    Liu, Xiangyu
    Yin, Zhenyu
    ONCOTARGETS AND THERAPY, 2020, 13 : 7941 - 7948
  • [26] Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation
    Park, Keunchil
    Chang, Gee-Chen
    Curigliano, Giuseppe
    Lim, Wan-Teck
    Soo, Ross A.
    Molina-Vila, Miguel A.
    Cattan, Valerie
    Darville, Helene
    Gandossi, Eric
    Smutna, Veronika
    Sudey, Isabelle
    Viteri, Santiago
    LUNG CANCER, 2021, 155 : 127 - 135
  • [27] Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?
    Zhang, Shannon S.
    Ou, Sai-hong Ignatius
    LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 67 - 73
  • [28] Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I+V774M): A Case Report
    Cosi, Donato Michele
    Fragale, Cristina
    Magri, Chiara
    Carnevale, Aldo
    Ciancetta, Antonella
    Guidoboni, Massimo
    Negrini, Massimo
    Bronte, Giuseppe
    Calabro, Luana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [29] Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer
    Osamu Ishimoto
    Takashi Ishida
    Yoshihiro Honda
    Mitsuru Munakata
    Shunichi Sugawara
    International Journal of Clinical Oncology, 2009, 14 : 43 - 47
  • [30] Impact of immunotherapy on the therapeutic strategy for the management of stage I non-small cell lung cancer: The radiation oncologist's point of view
    Khalifa, J.
    CANCER RADIOTHERAPIE, 2023, 27 (6-7): : 653 - 658